
Main Responsibilities of the National Medical Products Administration (1) To supervise the safety of drugs (including traditional Chinese medicines (TCMs) and ethno-medicines, the same below), medical devices and cosmetics; to draw up regulatory policy plans, organize the drafting of laws and regulations, formulate normative documents, and supervise the implementation thereof; to research and formulate regulatory and supportive policies that encourage new technologies and new products for drugs, medical devices and cosmetics. (2) To undertake standards management for drugs, medical devices and cosmetics; to organize the formulation and publication of the Chinese Pharmacopoeia and other drug and medical device standards, organize the drafting of cosmetic standards, organize the formulation of the classification management system, and supervise the implementation thereof; to participate in formulating the National Essential Medicine List, and assist in the implementation of the national essential medicine system. (3) To regulate the registration of drugs, medical devices and cosmetics; to develop the registration system, conduct strict review and approval for marketing, improve measures to facilitate the review and approval process, and organize the implementation thereof. (4) To undertake quality management for drugs, medical devices and cosmetics; to develop Good Laboratory Practices (GLP) and Good Clinical Practices (GCP), and supervise the implementation thereof; to develop Good Manufacturing Practices (GMP) and supervise the implementation thereof in line with NMPA's responsibilities; to develop good practices on the distribution and use of medical products and guide the implementation thereof.
解鎖市場時間軸與訊號動態
全新 合作夥伴 活動 — 剛出現 3 個新訊號。
此公司進入各市場的次序 — 由最舊至最新
安騰基因獲CDE批准進行ATG-022三期試驗
科倫博泰獲SKB118臨床試驗批准
註冊以查看完整訊號動態
NMPA-National Medical Products Administration 的國際擴張與競爭對手的比較
長條顯示所比較各公司之間的相對規模。
欄位5| 公司 | 市場 | 新市場 | 動能 | 活動 | 擴張評分 |
|---|---|---|---|---|---|
NMPA-National Medical Products Administration你 | 4 | 2 | +300% | 5 | 19 |
目前並無招聘
註冊以追蹤此公司,並在發生變化時第一時間獲得提醒。
暫無已追蹤技術
註冊以追蹤此公司,並在發生變化時第一時間獲得提醒。
無進行中的廣告活動
註冊以追蹤此公司,並在發生變化時第一時間獲得提醒。
Chance Pharmaceuticals宣布中國NMPA接受其CXG87新藥申請,這是一種創新的布地奈德/福莫特羅吸入粉劑,用於哮喘治療,標誌著公司首次新藥申請及商業化里程碑。
大塚製藥宣布斯貝利單抗(伊再可)獲中國NMPA批准用於IgA腎病,這是全球首個獲批的生物製劑,基於VISIONARY三期研究顯示9個月蛋白尿降低51.2%,為疾病進展風險患者提供新選擇。
恆瑞醫藥在2026年ASCO年會上公佈CARES-336三期研究結果,顯示卡瑞利珠單抗聯合阿帕替尼及TACE治療不可切除肝細胞癌患者的無進展生存期顯著改善。
解鎖已驗證電郵與直撥電話
免費 · 無需信用卡
關於 NMPA-National Medical Products Administration 業務、市場及增長訊號的快速解答。
